Authors
Latest:
Dr. Runaas on Impactful Targeted Therapies in FLT3-Positive AMLLyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).
Latest:
Dr. Sholl on Challenges With Using Tissue Biopsy for Biomarker Testing in Lung CancerLynette M. Sholl, MD, discusses the challenges faced with the use of tissue biopsy to test for biomarkers in lung cancer.
Latest:
Dr. Schuchter Discusses Nivolumab in MelanomaLynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.
Latest:
Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-ThalassemiaA majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).
Latest:
Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLCLyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Latest:
Current and Future Use of MET Inhibitors in NSCLCHealthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.
Latest:
Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin ShortagesExperts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.
Latest:
Dr. Hammond Discusses HER2 Testing Guideline RevisionsPathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.
Latest:
Dr. Rivera on the National Lung Screening TrialM. Patricia Rivera, MD, professor of medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses novel methods of detecting high-risk lung cancer.
Latest:
Developing Best Practices to Mitigate Opioid Abuse Is a Priority in Cancer CareOpioids are prescribed to manage cancer pain because the benefits generally outweigh the risks and because of the ethical imperative for quick relief. However, patients are exposed to a degree of risk for misuse and abuse.
Latest:
SPORE Grant Fuels New Research Projects on Neuroendocrine TumorsWith the FDA emphasis on personalized medicine for patients with orphan diseases, the National Cancer Institute has recently awarded a Neuroendocrine Tumor Specialized Program of Research Excellence to the Holden Comprehensive Cancer Center at the University of Iowa to fund both basic and clinical research on neuroendocrine tumors.
Latest:
Dr. Mrugala on Extending Treatment With Temozolomide in GlioblastomaMaciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.
Latest:
Management and Treatment of Interstitial Lung Disease in Breast CancerMadelaine Kuiper, MSN, RN, discusses the adverse event of interstitial lung disease, which can occur in patients with HER2-positive metastatic breast cancer who have received fam-trastuzumab deruxtecan-nxki.
Latest:
Dr. Duvic on Importance of Classifying T-Cell LymphomasMadeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.
Latest:
Value and Market Access Considerations Often Missing From Trial DesignHaving an evidence package at launch that satisfies payers’ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.
Latest:
Dr Dhodapkar on the Role of Linvoseltamab in Relapsed/Refractory Multiple MyelomaMadhav V. Dhodapkar, MBBS, discusses the advantages and disadvantages of bispecific antibodies and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma, as well as the potential role for the bispecific antibody linvoseltamab in this treatment paradigm.
Latest:
Dr. Vusirikala on Hyper-CVAD Plus Ponatinib in Philadelphia Chromosome-Positive ALLMadhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.
Latest:
PALB2 Mutations Confer Susceptibility to Familial Pancreatic Cancer and May Provide a Novel Targeted Therapeutic Approach to CancerGermline mutations in PALB2 have recently been shown to increase lifetime risk of pancreatic cancer and breast cancer, among other types.
Latest:
Dr. DiNome on Surgical Approaches in Patients With Breast CancerMaggie DiNome, MD, associate professor of surgery, University of California, Los Angeles Medical Center, discusses the evolution of surgical approaches in patients with breast cancer.
Latest:
Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU OncologyMaha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.
Latest:
Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate CancerMaha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.
Latest:
Dr. Hussain on Retrospective Analysis of the ARASENS trial in mHSPCMaha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Hussain on Meaningful Effect as an End Point in Prostate Cancer TrialsMaha Hussain, MD, FACP, FASCO, discusses the importance of meaningful effect in prostate cancer trials.
Latest:
Dr. Fazel on Trends in Surgical TrainingMaisam Fazel, FRCS, MS, MB BChir, of Imperial College Healthcare NHS Trust in the United Kingdom on Trends in Surgical Training
Latest:
A Day in the Life of a Military Hematology/ Oncology FellowAt 5:45 am, the alarm on my phone goes off. I have 20 minutes until my 2 boys wake up, which is just enough time to get ready for work and fix myself a cup of coffee.
Latest:
Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast CancerMaki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.
